17 results
8-K
EX-99.1
APGE
Apogee Therapeutics Inc.
13 May 24
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
7:05am
as described above, partially offset by higher interest income.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company seeking
424B4
APGE
Apogee Therapeutics Inc.
11 Mar 24
Prospectus supplement with pricing info
6:01am
by an applicable income tax treaty), which may be offset by certain U.S. source capital losses of the Non-U.S. Holder, provided the Non-U.S. Holder has timely
10-K
2023 FY
APGE
Apogee Therapeutics Inc.
5 Mar 24
Annual report
6:15am
to a net loss of $84.0 million, partially offset by non-cash charges of $6.1 million for equity-based compensation and net changes in our operating assets … , primarily due to a net loss of $39.8 million, partially offset by non-cash charges including $2.2 million for equity-based compensation expense
8-K
EX-99.1
ee8vx05
5 Mar 24
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
6:11am
DRS
l1e wqm1fq
9 Feb 24
Draft registration statement
12:00am
10-Q
0e8lmsl8
28 Aug 23
Quarterly report
8:00am
424B4
90z6q37n1v 3r
17 Jul 23
Prospectus supplement with pricing info
4:08pm
S-1
EX-3.1
yec98k
22 Jun 23
IPO registration
4:19pm
S-1
52kkgwihn
22 Jun 23
IPO registration
4:19pm
DRS/A
oyj1r2rt13e9zp 26
5 Jun 23
Draft registration statement (amended)
12:00am
DRS/A
EX-3.1
krv2xm4g6i mhnlc
5 Jun 23
Draft registration statement (amended)
12:00am
DRS
EX-3.1
93ggzxgq9579lh 0vid
28 Apr 23
Draft registration statement
12:00am
DRS
jgrg7zyl8q7
28 Apr 23
Draft registration statement
12:00am
- Prev
- 1
- Next